Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482440 · ClinicalTrials.gov registry record · Early Phase 1
Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
A Early Phase 1 study, sponsored by University of Iowa.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT03482440 is a Early Phase 1 study that has completed, run by University of Iowa. The registered enrollment target is 24 participants.
The verdict
NCT03482440, a Early Phase 1 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Women who develop preeclampsia during pregnancy are more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to 1) determine the mechanisms contributing to this lasting blood vessel damage and chronic inflammation, and to 2) identify factors (both physiological and pharmacological) that mitigate these negative effects in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Salsalate Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-08-26 |
| Est. Completion | 2022-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03482440
The ClinicalTrials.gov registry entry for NCT03482440 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03482440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03482440 about?
NCT03482440 is a clinical study titled "Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia". Women who develop preeclampsia during pregnancy are more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnanc...
What is the current status of trial NCT03482440?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2018-08-26. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03482440?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Salsalate Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03482440?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.